Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing ProteinsGlobeNewsWire • 10/14/20
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/20
Earnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to DeclineZacks Investment Research • 07/27/20
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare ConferenceGlobeNewsWire • 06/17/20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 05/29/20
Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate CancerGlobeNewsWire • 05/13/20
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/05/20
Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 PandemicGlobeNewsWire • 04/13/20
Arvinas to Present at the American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 03/31/20
Arvinas, Inc. (ARVN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/17/20